Myocarditis

To the Editor: Supportive care is the mainstay of therapy for acute myocarditis. In his review article on this topic, Cooper (April 9 issue)¹ notes that studies of immunosuppressive therapy have not shown a clear beneficial role, as compared with usual care. Thus, the beneficial effect of immunosuppressive therapy remains controversial. Treatment that is based on the presence of human leukocyte antigen may be associated with improved outcomes.¹ However, are there other ways to predict who is likely to benefit from immunosuppressive therapy? In one trial, prednisolone that was administered to patients who did not have a response to other . . .